The use of human pluripotent stem cells for cell-based therapeutics is predicated on the ability to convert these cells into functional equivalents of those lost in disease or injury. However,…
Human embryonic stem cells (hESC) have the potential to differentiate into all of the cell types that make up the body. Therefore, hESCs are promising tools for the treatment of…
The goal of this research is to utilize novel research tools to investigate the molecular mechanisms that cause Parkinson’s disease (PD). The proposed work builds on previous funding from CIRM…
Stem cell research offers new tools to help treat and cure diseases that affect diverse cells types in the body such as neurological diseases, heart disease and diabetes by producing…
Human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) provide an invaluable resource for regenerative medicine and disease modeling. To be able to use these cells in the…
The clinical potential of pluripotent stem cells for use in regenerative medicine will be realized only when the process by which tissues are generated from these cells is significantly more…
There remains an urgent and critical need for a cell-based cure of diabetes, one of the most costly diseases in California. Islet transplantation with persistent immune suppression has shown promise…
Induced pluripotent stem cells (iPSCs) have tremendous potential for patient-specific cell therapies, which bypasses immune rejection issues and ethical concerns for embryonic stem cells (ESCs). However, to fully harness the…
The 3D imaging techniques of CT and MRI have virtually eliminated the need for exploratory surgery – a procedure which was common in difficult cases just 20-30 years ago. Not…
This study will use Ataxia-Telangiectasia (A-T), an early-onset inherited neurodegenerative disease of children, as a model to study the mechanisms leading to cerebellar neurodegeneration and to develop a drug that…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
